Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1.

AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):899-907. Unique Identifier : AIDSLINE MED/99335212
Gilljam G; Svensson A; Ekstrom A; Wahren B; Swedish Institute for Infectious Disease Control, Karolinska; Institute, Stockholm.

Abstract: The outer envelope glycoprotein (gp120) from subtypes A-E of HIV-1 was purified using a specific high mannose-binding lectin, Galanthus nivalis agglutinin. All isolates were grown in peripheral blood lymphocyte cells in order to avoid selection in cell lines. A comparison of the reactivities of the envelope proteins was made using sera from patients infected with the different subtypes. In this study, the B and C subtype envelope glycoproteins showed the strongest immunological reactivity, when reacted with sera from patients infected with the same subtype of virus. On the other hand, sera of patients infected with subtype A or C virus had the strongest and broadest reactivities, to envelope glycoproteins of many subtypes. The purified gp120 proteins from all five subtypes stimulated mononuclear cells from HIV-1 (subtype B)-infected patients, indicating conserved T cell-activating epitopes. The immunological reactivities indicate that strong antigenicity does not always predict the broadest immunogenicity of an envelope glycoprotein. Glycoprotein 120 from foreign subtypes may serve to induce strong cross-reactive immune responses.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Binding, Competitive Glycoproteins/IMMUNOLOGY/ISOLATION & PURIF Human HIV Envelope Protein gp120/*IMMUNOLOGY/ISOLATION & PURIF HIV Infections/BLOOD/*IMMUNOLOGY HIV-1/*IMMUNOLOGY Molecular Sequence Data Peptide Fragments/*IMMUNOLOGY/ISOLATION & PURIF Support, Non-U.S. Gov't T-Lymphocytes/IMMUNOLOGY/VIROLOGY
991130
A99B1083

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .